Gilead Sciences Profile

74.44
USD 0.74  1.00%
17%
29%

Sale by Shultz George P of 700 shares of Gilead Sciences

Gilead Sciences insider trading alert for sale of common stock by Shultz George P, the corporate stakeholder, on April 19, 2018. This event was filed by Gilead Sciences Inc with SEC on 2005-05-06. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Gilead Sciences Summary

Gilead Sciences made a $10 billion bet and lost.? They invested heavily into a drug that was denied release by the FDA.? Naturally, the stock was sold off sharply.? While the stock was sitting at highs of nearly $50.00, it is now a mere 10% of the level now.? But, just because the stock is beaten down as it is, does that mean it is a bad bet? ? [more]
Gilead Sciences (GILD) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 10,000 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Large-Cap' category with current market capitalization of 98.68 B. Gilead Sciences conducts business under Healthcare sector and is part of Pharmaceuticals And Biosciences industry. This company has 1.3 B outstanding shares of which 19.99 M shares are currently shorted by private and institutional investors with about 2.14 trading days to cover. GILEAD SCIENCES currently holds about 26.14 B in cash with 11.34 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 19.96.
Check Gilead Sciences Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Below OddsHorizonTargetAbove Odds
about 16.17%30 days 74.44  about 83.64%
Based on normal probability distribution, the odds of Gilead Sciences to move above current price in 30 days from now is about 83.64% (This Gilead Sciences probability density function shows the probability of Gilead Sciences Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Bank Of MontrealCommon Shares3.3 M251.9 M
First Manhattan CoCommon Shares2.7 M207 M
View Gilead Sciences Diagnostics

Selected Gilead Sciences Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Gilead Sciences Against Markets

Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
< 1% 
Equity ratings for Gilead Sciences are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Biotechnology classification in USA and traded on NASDAQ. It employs 10000 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameGilead Sciences
Chairman and CEOJohn MartinView All
Thematic Classification
Currently Active Investing Idea
  Macroaxis Index
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Bond Rating
Specialization
Healthcare, Pharmaceuticals And Biosciences
InstrumentUSA Stock View All
RegionNorth America
LocationCALIFORNIA, U.S.A
Business Address333 Lakeside Drive
Foreign Associates
ExchangeNASDAQ
CIK Number00882095.0
ISINUS3755581036
CUSIP375558103
SectorHealthcare
IndustryPharmaceuticals And Biosciences
BenchmarkDOW
Websitewww.gilead.com
Contact Number650 574 3000
CurrencyUSD - US Dollar

Recommendations

Gilead Sciences Analyst Recommendations
Target PriceAdvice# of Analysts
93.29Buy14Odds
Gilead Sciences current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Gilead Sciences Analyst Advice  

Gilead Sciences Dividends

Upcoming distributions to stockholders

Earnings

Gilead Sciences Earnings Estimates
EPSEstimate Date
Quarterly Estimate2.15April 27, 2017
Gilead Sciences normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

Gilead Sciences Corporate Directors
Gayle Wilson Independent Director
Jacqueline Barton Director, Ph.D
John Madigan Independent Director
Please also check Risk vs Return Analysis. Please also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.